港股荣昌生物（09995.HK）今日盘中大涨17.85%，引发市场广泛关注。该股价格走势强劲，主要受益于公司多项临床研究进展以及机构投资者的增持。
据悉，美国临床肿瘤学会2025年年会（ASCO 2025）即将于5月底在芝加哥举行。荣昌生物20余项肿瘤管线临床进展或阶段性数据入选相关展示，其中包括维迪西妥单抗联合疗法一线治疗HER2表达胃癌的研究结果被选为口头报告。这一重要进展表明公司在肿瘤治疗领域的研发实力得到认可，提升了投资者对公司未来发展前景的信心。
此外，荣昌生物近期获得国际知名保险和资产管理集团安联（Allianz SE）增持，进一步提振了市场信心。根据港交所最新权益披露资料，Allianz SE于4月16日在场内增持荣昌生物257.55万股，持股比例从4.48%上升至5.83%。国际大型机构投资者的参与被视为对公司发展前景的看好，可能为荣昌生物带来更多的资金支持和国际关注度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.